CD44 exerts a functional role during EMT induction in cisplatin-resistant head and neck cancer cells

Hiroaki Miyazaki; Ryou-u Takahashi; Marta Prieto-Vila; Yumi Kawamura; Seiji Kondo; Tatsuo Shirota; Takahiro Ochiya

doi:10.18632/oncotarget.24252

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CD44 exerts a functional role during EMT induction in cisplatin-resistant head and neck cancer cells

Hiroaki Miyazaki _, Ryou-u Takahashi, Marta Prieto-Vila, Yumi Kawamura, Seiji Kondo, Tatsuo Shirota and Takahiro Ochiya

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:10029-10041. https://doi.org/10.18632/oncotarget.24252

Metrics: PDF 1800 views | HTML 2962 views | ?

Abstract

Hiroaki Miyazaki1,2, Ryou-u Takahashi1, Marta Prieto-Vila1, Yumi Kawamura1,3, Seiji Kondo2, Tatsuo Shirota2 and Takahiro Ochiya1

1Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo 104-0045, Japan

2Department of Oral and Maxillofacial Surgery, Showa University School of Dentistry, Tokyo 145-8515, Japan

3Ph.D. Program in Human Biology, School of Integrative and Global Majors, University of Tsukuba 1-1-1 Tennodai, Ibaraki 305-8577, Japan

Correspondence to:

Takahiro Ochiya, email: [email protected]

Keywords: oral cancer, CD44, EMT, cancer stem cell niche

Received: January 12, 2017 Accepted: August 31, 2017 Published: January 13, 2018

ABSTRACT

A number of studies report that epithelial to mesenchymal transition (EMT) supports the generation and maintenance of cancer stem cells (CSCs), which show tumor seeding ability and drug resistance; however, the molecular mechanisms underlying induction of EMT-associated tumor malignancy remain unclear. The present study reports that oral cancer cells switch from expressing the CD44 variant form (CD44v) to expressing the standard form (CD44s) during acquisition of cisplatin-resistance, which resulted in EMT induction. CD44s induced an EMT phenotype in cisplatin resistant cells by up-regulating ZEB1, a transcriptional repressor of E-cadherin. More importantly, CD44s up-regulated ZEB1 by suppressing microRNA-200c, which is a non-coding RNA that directly represses the ZEB1 gene. These results demonstrate the importance of the association between platinum resistance and CD44s during EMT induction in oral cancer cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24252

Publication Alerts

Research Papers:

CD44 exerts a functional role during EMT induction in cisplatin-resistant head and neck cancer cells

Abstract